Akeso Eulerpool Ziņas

Akeso Eulerpool News

Akeso Akciju Ziņas

Akeso tiek uzmanīgi vēroti no žurnālistu un investoru puses visā pasaulē. Jaunākās Akeso ziņas mēs apkopojam šeit.

• 15. augusts ·

  Yahoo
  Ivonescimab (PD-1/VEGF) Received Priority Review from China's NMPA for First-Line Treatment of PD-L1 Positive NSCLC
• 12. augusts ·

  Yahoo
  Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024
• 6. augusts ·

  Yahoo
  First Patient Enrolled in the US Phase 2 Combination Therapy of Akeso's Ligufalimab with Azacitidine for Myelodysplastic Syndrome
• 29. jūlijs ·

  Yahoo
  Akeso's sBLA for Ivonescimab in 1L Treatment of PD-L1 Positive NSCLC Accepted by NMPA
• 9. jūnijs ·

  SeekingAlpha
  Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476M
• 2. jūnijs ·

  SeekingAlpha
  Week In Review: MediLink And BioNTech Form $1.8B ADC Partnership
• 1. jūnijs ·

  Yahoo
  ASCO24: Akeso’s bispecific vvonescimab faces a rocky road ahead in NSCLC
• 1. jūnijs ·

  Yahoo
  Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
• 30. maijs ·

  Yahoo
  Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC
• 8. maijs ·

  SeekingAlpha
  Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide